<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.pharmacytimes.com/view/ppi-antibiotic-exposure-associated-with-attenuated-immunotherapy-benefit-in-stage-3-nsclc</loc><lastmod>2026-07-16T16:00:00Z</lastmod><news:news><news:publication_date>2026-07-16T16:00:00Z</news:publication_date>
        <news:title><![CDATA[PPI, Antibiotic Exposure Associated With Attenuated Immunotherapy Benefit in Stage 3 NSCLC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/standardized-protocols-help-bring-bite-therapy-into-the-outpatient-setting</loc><lastmod>2026-07-16T15:20:55.433Z</lastmod><news:news><news:publication_date>2026-07-16T15:20:55.433Z</news:publication_date>
        <news:title><![CDATA[Standardized Protocols Help Bring BiTE Therapy Into the Outpatient Setting]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/promising-phase-2-and-3-influenza-therapies-what-pharmacists-should-know</loc><lastmod>2026-07-16T15:18:02.884Z</lastmod><news:news><news:publication_date>2026-07-16T15:18:02.884Z</news:publication_date>
        <news:title><![CDATA[Promising Phase 2 and 3 Influenza Therapies: What Pharmacists Should Know]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/standardized-protocols-support-safe-outpatient-bispecific-step-up-dosing</loc><lastmod>2026-07-16T15:06:59.730Z</lastmod><news:news><news:publication_date>2026-07-16T15:06:59.730Z</news:publication_date>
        <news:title><![CDATA[Standardized Protocols Support Safe Outpatient Bispecific Step-Up Dosing]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-accepts-nda-for-axs-12-for-the-treatment-of-cataplexy-in-narcolepsy</loc><lastmod>2026-07-16T14:53:52.216Z</lastmod><news:news><news:publication_date>2026-07-16T14:53:52.216Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-enlicitide-the-first-oral-pcsk9-inhibitor-for-high-cholesterol</loc><lastmod>2026-07-16T12:42:39.278Z</lastmod><news:news><news:publication_date>2026-07-16T12:42:39.278Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/navigating-dosing-frequency-with-revumenib-and-ziftomenib</loc><lastmod>2026-07-16T12:20:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:20:00Z</news:publication_date>
        <news:title><![CDATA[Navigating Dosing Frequency With Revumenib and Ziftomenib]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/differentiating-revumenib-and-ziftomenib-label-vs-perception</loc><lastmod>2026-07-16T12:15:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:15:00Z</news:publication_date>
        <news:title><![CDATA[Differentiating Revumenib and Ziftomenib: Label vs Perception]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/choosing-between-revumenib-and-ziftomenib-for-patients-with-npm1-mutations</loc><lastmod>2026-07-16T12:10:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:10:00Z</news:publication_date>
        <news:title><![CDATA[Choosing Between Revumenib and Ziftomenib for Patients With NPM1 Mutations]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/from-dreamm-7-to-dreamm-8-clinical-evidence-conference-updates-and-managing-belantamab-mafodotin-adverse-events</loc><lastmod>2026-07-16T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:05:00Z</news:publication_date>
        <news:title><![CDATA[From DREAMM-7 to DREAMM-8: Clinical Evidence, Conference Updates, and Managing Belantamab Mafodotin Adverse Events]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/clinical-evidence-what-the-trial-data-tell-pharmacists</loc><lastmod>2026-07-16T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Evidence: What the Trial Data Tell Pharmacists]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/shifting-the-paradigm-evidence-earlier-use-and-sequencing-of-bcma-targeted-therapies-in-relapsed-refractory-multiple-myeloma</loc><lastmod>2026-07-16T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Shifting the Paradigm: Evidence, Earlier Use, and Sequencing of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/historic-treatments-and-the-need-for-menin-inhibitors</loc><lastmod>2026-07-16T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-16T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Historic Treatments and the Need for Menin Inhibitors]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/patient-reported-outcomes-machine-learning-may-predict-breast-cancer-recurrence-earlier</loc><lastmod>2026-07-15T16:30:00Z</lastmod><news:news><news:publication_date>2026-07-15T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/machine-learning-update-to-martin-hopkins-equation-improves-ldl-c-accuracy-for-labs</loc><lastmod>2026-07-15T15:30:00Z</lastmod><news:news><news:publication_date>2026-07-15T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Machine Learning Update to Martin-Hopkins Equation Improves LDL-C Accuracy for Labs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/rural-health-transformation-efforts-offer-an-opportunity-for-pharmacy-to-shine</loc><lastmod>2026-07-15T14:59:38.066Z</lastmod><news:news><news:publication_date>2026-07-15T14:59:38.066Z</news:publication_date>
        <news:title><![CDATA[Rural Health Transformation Efforts Offer an Opportunity for Pharmacy to Shine]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/how-aon-built-an-outpatient-bite-therapy-program-for-multiple-myeloma</loc><lastmod>2026-07-15T14:32:43.697Z</lastmod><news:news><news:publication_date>2026-07-15T14:32:43.697Z</news:publication_date>
        <news:title><![CDATA[How AON Built an Outpatient BiTE Therapy Program for Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/expert-q-a-what-the-mmrv-vaccine-equity-data-means-for-pharmacists</loc><lastmod>2026-07-15T14:30:00Z</lastmod><news:news><news:publication_date>2026-07-15T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Expert Q&A: What the MMRV Vaccine Equity Data Means for Pharmacists]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/outpatient-bispecific-step-up-dosing-expands-despite-operational-barriers</loc><lastmod>2026-07-15T14:11:18.489Z</lastmod><news:news><news:publication_date>2026-07-15T14:11:18.489Z</news:publication_date>
        <news:title><![CDATA[Outpatient Bispecific Step-Up Dosing Expands Despite Operational Barriers]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacist-led-monitoring-boosts-resmetirom-lab-adherence-cuts-discontinuation-in-mash-study</loc><lastmod>2026-07-15T13:47:49.202Z</lastmod><news:news><news:publication_date>2026-07-15T13:47:49.202Z</news:publication_date>
        <news:title><![CDATA[Pharmacist-Led Monitoring Boosts Resmetirom Lab Adherence, Cuts Discontinuation in MASH Study]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/subcutaneous-olanzapine-in-schizophrenia-expanding-the-utility-of-a-proven-therapy</loc><lastmod>2026-07-15T13:18:54.508Z</lastmod><news:news><news:publication_date>2026-07-15T13:18:54.508Z</news:publication_date>
        <news:title><![CDATA[Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/remote-patient-monitoring-in-myeloma-how-technology-is-transforming-bispecific-antibody-management</loc><lastmod>2026-06-30T12:05:00.000Z</lastmod><news:news><news:publication_date>2026-07-15T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/when-transitions-break-down-real-world-challenges-and-lessons-learned-in-myeloma-care-handoffs</loc><lastmod>2026-06-30T12:05:00.000Z</lastmod><news:news><news:publication_date>2026-07-15T12:00:00Z</news:publication_date>
        <news:title><![CDATA[When Transitions Break Down: Real-World Challenges and Lessons Learned in Myeloma Care Handoffs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacist-led-pathways-help-health-systems-balance-opioid-stewardship-and-acute-pain-relief</loc><lastmod>2026-07-14T21:30:54.618Z</lastmod><news:news><news:publication_date>2026-07-14T21:30:54.618Z</news:publication_date>
        <news:title><![CDATA[Pharmacist-Led Pathways Help Health Systems Balance Opioid Stewardship and Acute Pain Relief]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/gedatolisib-combination-approved-for-pik3ca-wild-type-hr-her2-breast-cancer</loc><lastmod>2026-07-14T20:31:52.675Z</lastmod><news:news><news:publication_date>2026-07-14T20:31:52.675Z</news:publication_date>
        <news:title><![CDATA[Gedatolisib Combination Approved for PIK3CA Wild-Type HR+, HER2– Breast Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/cyclosporiasis-cases-reach-5100-investigators-zero-in-on-lettuce-possible-taco-bell-link</loc><lastmod>2026-07-14T19:41:00Z</lastmod><news:news><news:publication_date>2026-07-14T19:41:00Z</news:publication_date>
        <news:title><![CDATA[Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-grants-traditional-approval-to-selpercatinib-for-ret-fusion-positive-solid-tumors-across-multiple-cancer-types</loc><lastmod>2026-07-14T18:58:00Z</lastmod><news:news><news:publication_date>2026-07-14T18:58:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors Across Multiple Cancer Types]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/anemia-in-multiple-myeloma-mechanisms-management-and-emerging-therapies</loc><lastmod>2026-07-14T17:24:56.460Z</lastmod><news:news><news:publication_date>2026-07-14T17:24:56.460Z</news:publication_date>
        <news:title><![CDATA[Anemia in Multiple Myeloma: Mechanisms, Management, and Emerging Therapies]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/from-assessment-to-discharge-pharmacists-drive-safer-patient-centered-acute-pain-management</loc><lastmod>2026-07-14T15:36:24.683Z</lastmod><news:news><news:publication_date>2026-07-14T15:36:24.683Z</news:publication_date>
        <news:title><![CDATA[From Assessment to Discharge: Pharmacists Drive Safer, Patient-Centered Acute Pain Management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/medicare-and-weight-loss-medications-a-pharmacist-s-faq-on-the-glp-1-bridge-program</loc><lastmod>2026-07-14T14:30:00Z</lastmod><news:news><news:publication_date>2026-07-14T14:30:00Z</news:publication_date>
        <news:title><![CDATA[Medicare and Weight-Loss Medications: A Pharmacist's FAQ on the GLP-1 Bridge Program]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/psychedelics-in-cluster-headaches-are-breaking-the-pain-cycle</loc><lastmod>2026-07-14T13:38:47.187Z</lastmod><news:news><news:publication_date>2026-07-14T13:38:47.187Z</news:publication_date>
        <news:title><![CDATA[Psychedelics in Cluster Headaches Are Breaking the Pain Cycle]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/charting-a-responsible-course-for-ai</loc><lastmod>2026-07-14T13:16:00Z</lastmod><news:news><news:publication_date>2026-07-14T13:16:00Z</news:publication_date>
        <news:title><![CDATA[Charting a Responsible Course for AI]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/differentiating-vmat2-inhibitors-long-term-management-and-safety-data-that-builds-confidence</loc><lastmod>2026-07-14T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-14T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Differentiating VMAT2 Inhibitors: Long-Term Management and Safety Data That Builds Confidence]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/communicating-early-treatment-benefits-and-navigating-vmat2-inhibitor-dosing-in-tardive-dyskinesia</loc><lastmod>2026-07-14T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-14T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Communicating Early Treatment Benefits and Navigating VMAT2 Inhibitor Dosing in Tardive Dyskinesia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-at-home-starting-dose-of-lecanemab-for-treatment-of-alzheimer-disease</loc><lastmod>2026-07-13T20:13:38.441Z</lastmod><news:news><news:publication_date>2026-07-13T20:13:38.441Z</news:publication_date>
        <news:title><![CDATA[FDA Approves At-Home Starting Dose of Lecanemab for Treatment of Alzheimer Disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/ai-and-drug-information-where-openevidence-stands-out-and-where-pharmacists-still-win</loc><lastmod>2026-07-13T19:55:01.596Z</lastmod><news:news><news:publication_date>2026-07-13T19:55:01.596Z</news:publication_date>
        <news:title><![CDATA[AI and Drug Information: Where OpenEvidence Stands Out—and Where Pharmacists Still Win]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/evaluation-of-a-pharmacist-driven-discharge-medication-reconciliation-service</loc><lastmod>2026-07-13T19:45:36.529Z</lastmod><news:news><news:publication_date>2026-07-13T19:45:36.529Z</news:publication_date>
        <news:title><![CDATA[Evaluation of a Pharmacist-Driven Discharge Medication Reconciliation Service]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/closing-the-kidney-gap-in-cardio-kidney-metabolic-care</loc><lastmod>2026-07-13T18:23:00Z</lastmod><news:news><news:publication_date>2026-07-13T18:23:00Z</news:publication_date>
        <news:title><![CDATA[Closing the Kidney Gap in Cardio-Kidney-Metabolic Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/oncology-pulsepoint-asco-updates-targeted-therapy-for-stage-iv-nsclc</loc><lastmod>2026-07-13T18:04:00Z</lastmod><news:news><news:publication_date>2026-07-13T18:04:00Z</news:publication_date>
        <news:title><![CDATA[Oncology PulsePoint: ASCO Updates Targeted Therapy for Stage IV NSCLC]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacists-can-catch-missed-ckd-with-one-question</loc><lastmod>2026-07-13T15:30:00Z</lastmod><news:news><news:publication_date>2026-07-13T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Pharmacists Can Catch Missed CKD With One Question ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/psychedelic-therapy-and-veterans-what-pharmacists-need-to-know-about-the-right-to-try-pathway-for-ibogaine</loc><lastmod>2026-07-13T15:24:23.599Z</lastmod><news:news><news:publication_date>2026-07-13T15:24:23.599Z</news:publication_date>
        <news:title><![CDATA[Psychedelic Therapy and Veterans: What Pharmacists Need to Know About the Right to Try Pathway for Ibogaine]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacists-can-help-patients-navigate-glp-1-access-affordability-and-long-term-use</loc><lastmod>2026-07-11T15:12:00Z</lastmod><news:news><news:publication_date>2026-07-11T15:12:00Z</news:publication_date>
        <news:title><![CDATA[Pharmacists Can Help Patients Navigate GLP-1 Access, Affordability, and Long-Term Use]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/glp-1-ras-linked-to-lower-mortality-amputation-risk-in-patients-with-pad-and-type-2-diabetes</loc><lastmod>2026-07-10T20:40:00Z</lastmod><news:news><news:publication_date>2026-07-10T20:40:00Z</news:publication_date>
        <news:title><![CDATA[GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/key-counseling-points-for-otc-medications-during-pregnancy</loc><lastmod>2026-07-10T20:16:00Z</lastmod><news:news><news:publication_date>2026-07-10T20:16:00Z</news:publication_date>
        <news:title><![CDATA[Key Counseling Points for OTC Medications During Pregnancy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/the-weekly-dose-rising-cyclosporiasis-cases-psychedelic-therapy-safety-monitoring-and-new-fda-approvals</loc><lastmod>2026-07-10T19:04:21.543Z</lastmod><news:news><news:publication_date>2026-07-10T19:04:21.543Z</news:publication_date>
        <news:title><![CDATA[The Weekly Dose: Rising Cyclosporiasis Cases, Psychedelic Therapy Safety Monitoring, and New FDA Approvals]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/how-pharmacy-s-newest-board-certification-pioneers-pain-and-palliative-care</loc><lastmod>2026-07-10T17:30:49.595Z</lastmod><news:news><news:publication_date>2026-07-10T17:30:49.595Z</news:publication_date>
        <news:title><![CDATA[How Pharmacy's Newest Board Certification Pioneers Pain and Palliative Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/ai-prescription-refills-spark-debate-over-safety-oversight-and-the-future-of-clinical-care</loc><lastmod>2026-07-10T17:08:00Z</lastmod><news:news><news:publication_date>2026-07-10T17:08:00Z</news:publication_date>
        <news:title><![CDATA[AI Prescription Refills Spark Debate Over Safety, Oversight, and the Future of Clinical Care]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/minoritized-low-income-families-may-be-disproportionately-affected-by-mmrv-vaccine-withdrawal</loc><lastmod>2026-07-10T16:35:18.921Z</lastmod><news:news><news:publication_date>2026-07-10T16:35:18.921Z</news:publication_date>
        <news:title><![CDATA[Minoritized, Low-Income Families May Be Disproportionately Affected By MMRV Vaccine Withdrawal]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pembrolizumab-plus-ev-regimens-receive-fda-approval-for-muscle-invasive-bladder-cancer</loc><lastmod>2026-07-10T15:47:43.302Z</lastmod><news:news><news:publication_date>2026-07-10T15:47:43.302Z</news:publication_date>
        <news:title><![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle-Invasive Bladder Cancer]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/isatuximab-wins-fda-approval-becoming-second-subcutaneous-anti-cd38-for-multiple-myeloma</loc><lastmod>2026-07-10T14:50:34.581Z</lastmod><news:news><news:publication_date>2026-07-10T14:50:34.581Z</news:publication_date>
        <news:title><![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/aon-shares-lessons-for-building-safe-outpatient-bite-therapy-programs</loc><lastmod>2026-07-10T14:15:43.870Z</lastmod><news:news><news:publication_date>2026-07-10T14:15:43.870Z</news:publication_date>
        <news:title><![CDATA[AON Shares Lessons for Building Safe Outpatient BiTE Therapy Programs]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/navigating-coverage-and-cost-what-pharmacists-need-to-know-about-access-to-non-hormonal-vms-therapies</loc><lastmod>2026-07-10T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-10T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Navigating Coverage and Cost: What Pharmacists Need to Know About Access to Non-Hormonal VMS Therapies]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/the-proactive-pharmacist-building-menopause-knowledge-and-closing-care-gaps-in-the-community</loc><lastmod>2026-07-10T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-10T12:00:00Z</news:publication_date>
        <news:title><![CDATA[The Proactive Pharmacist: Building Menopause Knowledge and Closing Care Gaps in the Community]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-expands-wilate-approval-for-routine-prophylaxis-in-children-younger-than-6-with-von-willebrand-disease</loc><lastmod>2026-07-09T20:10:55.256Z</lastmod><news:news><news:publication_date>2026-07-09T20:10:55.256Z</news:publication_date>
        <news:title><![CDATA[FDA Expands Wilate Approval for Routine Prophylaxis in Children Younger Than 6 With von Willebrand Disease]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/opioid-use-for-acute-pain-was-typically-low-dose-and-short-duration-but-leftover-medication-remained-common</loc><lastmod>2026-07-09T20:05:47.092Z</lastmod><news:news><news:publication_date>2026-07-09T20:05:47.092Z</news:publication_date>
        <news:title><![CDATA[Opioid Use for Acute Pain Was Typically Low Dose and Short Duration, but Leftover Medication Remained Common]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/ai-test-predicts-breast-cancer-recurrence-using-standard-pathology-slides</loc><lastmod>2026-07-09T19:49:00Z</lastmod><news:news><news:publication_date>2026-07-09T19:49:00Z</news:publication_date>
        <news:title><![CDATA[AI Test Predicts Breast Cancer Recurrence Using Standard Pathology Slides]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-ennumo-pegfilgrastim-biosimilar-referencing-neulasta-for-febrile-neutropenia-and-radiation-exposure</loc><lastmod>2026-07-09T18:07:14.320Z</lastmod><news:news><news:publication_date>2026-07-09T18:07:14.320Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Ennumo, Pegfilgrastim Biosimilar Referencing Neulasta, for Febrile Neutropenia and Radiation Exposure]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/medicare-s-new-glp-1-bridge-program-what-pharmacists-need-to-know-before-dispensing</loc><lastmod>2026-07-09T18:00:00Z</lastmod><news:news><news:publication_date>2026-07-09T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/clots-catheters-and-clinical-pearls-pulmonary-embolism-updates-for-practicing-pharmacists</loc><lastmod>2026-07-09T17:42:10.888Z</lastmod><news:news><news:publication_date>2026-07-09T17:42:10.888Z</news:publication_date>
        <news:title><![CDATA[Clots, Catheters, and Clinical Pearls: Pulmonary Embolism Updates for Practicing Pharmacists]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacists-can-help-shape-the-future-of-glp-1-access</loc><lastmod>2026-07-09T15:37:20.614Z</lastmod><news:news><news:publication_date>2026-07-09T15:37:20.614Z</news:publication_date>
        <news:title><![CDATA[Pharmacists Can Help Shape the Future of GLP-1 Access]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacist-led-pathways-help-health-systems-balance-opioid-stewardship-acute-pain-relief</loc><lastmod>2026-07-09T14:18:30.619Z</lastmod><news:news><news:publication_date>2026-07-09T14:18:30.619Z</news:publication_date>
        <news:title><![CDATA[Pharmacist-Led Pathways Help Health Systems Balance Opioid Stewardship, Acute Pain Relief]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/single-shot-respiratory-vaccine-could-transform-pharmacist-counseling-and-immunization-rates</loc><lastmod>2026-07-09T13:38:47.339Z</lastmod><news:news><news:publication_date>2026-07-09T13:38:47.339Z</news:publication_date>
        <news:title><![CDATA[Single-Shot Respiratory Vaccine Could Transform Pharmacist Counseling and Immunization Rates]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/bcma-biology-mechanisms-of-action-and-unmet-needs-in-relapsed-refractory-multiple-myeloma</loc><lastmod>2026-07-09T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-09T12:05:00Z</news:publication_date>
        <news:title><![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/rationale-and-timing-the-evolving-role-of-bcma-targeted-therapies-in-relapsed-refractory-multiple-myeloma</loc><lastmod>2026-07-09T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-09T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/kidney-disease-rates-hold-steady-for-a-decade-as-diabetes-driven-cases-climb</loc><lastmod>2026-07-08T22:00:00Z</lastmod><news:news><news:publication_date>2026-07-08T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Kidney Disease Rates Hold Steady for a Decade as Diabetes-Driven Cases Climb]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacists-and-continuous-glucose-monitoring-an-attachment-worth-having</loc><lastmod>2026-07-08T19:09:00Z</lastmod><news:news><news:publication_date>2026-07-08T19:09:00Z</news:publication_date>
        <news:title><![CDATA[Pharmacists and Continuous Glucose Monitoring: An Attachment Worth Having]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/reducing-recurrence-in-clostridioides-difficile-infection</loc><lastmod>2026-07-08T17:00:00Z</lastmod><news:news><news:publication_date>2026-07-08T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Reducing Recurrence in C Difficile Infection]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/challenging-obesity-paradox-obesity-driven-immune-suppression-may-increase-nsclc-risk</loc><lastmod>2026-07-08T16:00:00Z</lastmod><news:news><news:publication_date>2026-07-08T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Challenging “Obesity Paradox,” Obesity-Driven Immune Suppression May Increase NSCLC Risk]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/same-day-covid-19-and-flu-vaccination-does-not-raise-adverse-event-risk-large-va-study-finds</loc><lastmod>2026-07-08T14:44:00Z</lastmod><news:news><news:publication_date>2026-07-08T14:44:00Z</news:publication_date>
        <news:title><![CDATA[Same-Day COVID-19 and Flu Vaccination Does Not Raise Adverse Event Risk, Large VA Study Finds]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/pharmacist-led-workflows-support-safe-outpatient-bite-therapy-in-multiple-myeloma</loc><lastmod>2026-07-08T14:15:00.821Z</lastmod><news:news><news:publication_date>2026-07-08T14:15:00.821Z</news:publication_date>
        <news:title><![CDATA[Pharmacist-Led Workflows Support Safe Outpatient BiTE Therapy in Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/study-links-several-progestogen-contraceptives-to-rare-meningioma-risk-reinforcing-individualized-patient-counseling</loc><lastmod>2026-07-08T14:00:00Z</lastmod><news:news><news:publication_date>2026-07-08T14:00:00Z</news:publication_date>
        <news:title><![CDATA[Study Links Several Progestogen Contraceptives to Rare Meningioma Risk, Reinforcing Individualized Patient Counseling]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/glp-1-access-depends-on-smarter-benefit-design-and-patient-support</loc><lastmod>2026-07-08T13:14:21.089Z</lastmod><news:news><news:publication_date>2026-07-08T13:14:21.089Z</news:publication_date>
        <news:title><![CDATA[GLP-1 Access Depends on Smarter Benefit Design and Patient Support]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/roles-resources-and-relationships-the-stakeholder-framework-behind-successful-myeloma-care-transitions</loc><lastmod>2026-06-30T12:05:00.000Z</lastmod><news:news><news:publication_date>2026-07-08T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Roles, Resources, and Relationships: The Stakeholder Framework Behind Successful Myeloma Care Transitions]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/when-it-works-best-case-scenarios-and-lessons-learned-from-successful-care-transitions-in-myeloma</loc><lastmod>2026-06-30T12:05:00.000Z</lastmod><news:news><news:publication_date>2026-07-08T12:00:00Z</news:publication_date>
        <news:title><![CDATA[When It Works: Best-Case Scenarios and Lessons Learned From Successful Care Transitions in Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/cyclosporiasis-on-the-rise-in-the-united-states-exceeding-450-cases</loc><lastmod>2026-07-07T20:24:00Z</lastmod><news:news><news:publication_date>2026-07-07T20:24:00Z</news:publication_date>
        <news:title><![CDATA[Cyclosporiasis on the Rise in the United States, Exceeding 450 Cases]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/usp-s-matt-christian-why-drug-shortages-are-becoming-longer-and-harder-to-solve</loc><lastmod>2026-07-07T20:21:13.796Z</lastmod><news:news><news:publication_date>2026-07-07T20:21:13.796Z</news:publication_date>
        <news:title><![CDATA[USP's Matt Christian: Why Drug Shortages Are Becoming Longer—and Harder to Solve]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/outpatient-bite-therapy-model-expands-access-for-patients-with-multiple-myeloma</loc><lastmod>2026-07-07T20:18:42.011Z</lastmod><news:news><news:publication_date>2026-07-07T20:18:42.011Z</news:publication_date>
        <news:title><![CDATA[Outpatient BiTE Therapy Model Expands Access for Patients With Multiple Myeloma]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-approves-atacicept-vymj-to-reduce-proteinuria-in-iga-nephropathy</loc><lastmod>2026-07-07T19:16:00Z</lastmod><news:news><news:publication_date>2026-07-07T19:16:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Atacicept-vymj to Reduce Proteinuria in IgA Nephropathy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/for-20-years-neiap-serves-as-community-for-ambulatory-care-pharmacists</loc><lastmod>2026-07-07T18:47:13.184Z</lastmod><news:news><news:publication_date>2026-07-07T18:47:13.184Z</news:publication_date>
        <news:title><![CDATA[For 20 Years, NEIAP Serves as Community for Ambulatory Care Pharmacists]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/new-ckm-guideline-elevates-pharmacists-role-in-comprehensive-medication-management</loc><lastmod>2026-07-07T18:23:40.526Z</lastmod><news:news><news:publication_date>2026-07-07T18:23:40.526Z</news:publication_date>
        <news:title><![CDATA[New CKM Guideline Elevates Pharmacists' Role in Comprehensive Medication Management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/sglt2-inhibitors-diabetes-tech-and-hypertension-take-center-stage-at-the-september-neiap-annual-forum</loc><lastmod>2026-07-07T18:14:05.173Z</lastmod><news:news><news:publication_date>2026-07-07T18:14:05.173Z</news:publication_date>
        <news:title><![CDATA[SGLT2 Inhibitors, Diabetes Tech, and Hypertension Take Center Stage at the September NEIAP Annual Forum]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/the-emerging-risks-of-modern-cannabis</loc><lastmod>2026-07-07T18:09:55.263Z</lastmod><news:news><news:publication_date>2026-07-07T18:09:55.263Z</news:publication_date>
        <news:title><![CDATA[The Emerging Risks of Modern Cannabis]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/upcoming-ncpa-events-for-pharmacy-teams-july-and-august-2026</loc><lastmod>2026-07-07T17:04:35.654Z</lastmod><news:news><news:publication_date>2026-07-07T17:04:35.654Z</news:publication_date>
        <news:title><![CDATA[Upcoming NCPA Events for Pharmacy Teams: July and August 2026]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/putting-patients-first-to-drive-antimicrobial-stewardship-improvements</loc><lastmod>2026-07-07T15:52:31.212Z</lastmod><news:news><news:publication_date>2026-07-07T15:52:31.212Z</news:publication_date>
        <news:title><![CDATA[Putting Patients First to Drive Antimicrobial Stewardship Improvements]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/from-observation-to-treatment-the-role-of-caregivers-and-overcoming-vmat2-inhibitor-complexities</loc><lastmod>2026-07-07T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-07T12:05:00Z</news:publication_date>
        <news:title><![CDATA[From Observation to Treatment: The Role of Caregivers and Overcoming VMAT2 Inhibitor Complexities]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/beyond-the-movement-td-s-impact-on-the-patient-journey-and-gaps-in-clinical-discussion</loc><lastmod>2026-07-07T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-07T12:00:00Z</news:publication_date>
        <news:title><![CDATA[Beyond the Movement: TD's Impact on the Patient Journey and Gaps in Clinical Discussion]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/sustainable-glp-1-coverage-requires-more-than-cost-control</loc><lastmod>2026-07-06T19:11:27.036Z</lastmod><news:news><news:publication_date>2026-07-06T19:11:27.036Z</news:publication_date>
        <news:title><![CDATA[Sustainable GLP-1 Coverage Requires Balancing Access, Cost, and Long-Term Value]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/neiap-delivers-a-necessary-network-for-ambulatory-care-pharmacists</loc><lastmod>2026-07-06T18:40:19.886Z</lastmod><news:news><news:publication_date>2026-07-06T18:40:19.886Z</news:publication_date>
        <news:title><![CDATA[NEIAP Delivers a Necessary Network for Ambulatory Care Pharmacists]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/neiap-is-evolving-to-meet-the-changing-needs-of-ambulatory-care-pharmacy</loc><lastmod>2026-07-06T17:02:49.127Z</lastmod><news:news><news:publication_date>2026-07-06T17:02:49.127Z</news:publication_date>
        <news:title><![CDATA[NEIAP Is Evolving to Meet the Changing Needs of Ambulatory Care Pharmacy]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/functional-cure-of-hepatitis-b-infections-among-patients-coinfected-with-hiv</loc><lastmod>2026-07-06T15:30:08.897Z</lastmod><news:news><news:publication_date>2026-07-06T15:30:08.897Z</news:publication_date>
        <news:title><![CDATA[Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/fda-expands-casgevy-approval-to-children-as-young-as-2-years-with-sickle-cell-disease-or-transfusion-dependent--thalassemia</loc><lastmod>2026-07-06T14:35:10.539Z</lastmod><news:news><news:publication_date>2026-07-06T14:35:10.539Z</news:publication_date>
        <news:title><![CDATA[FDA Expands Casgevy Approval to Children as Young as 2 Years With Sickle Cell Disease or Transfusion-Dependent β-Thalassemia]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/targeting-aldosterone-at-its-source-the-arrival-of-baxdrostat-for-resistant-hypertension</loc><lastmod>2026-07-06T13:46:00Z</lastmod><news:news><news:publication_date>2026-07-06T13:46:00Z</news:publication_date>
        <news:title><![CDATA[Targeting Aldosterone at Its Source: The Arrival of Baxdrostat for Resistant Hypertension]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/connecting-care-in-a-changing-health-system</loc><lastmod>2026-07-05T14:00:00Z</lastmod><news:news><news:publication_date>2026-07-05T14:00:00Z</news:publication_date>
        <news:title><![CDATA[Connecting Care in a Changing Health System]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/why-stanford-harvard-and-yale-are-betting-on-psychedelics</loc><lastmod>2026-07-04T15:08:00Z</lastmod><news:news><news:publication_date>2026-07-04T15:08:00Z</news:publication_date>
        <news:title><![CDATA[Why Stanford, Harvard, and Yale Are Betting on Psychedelics ]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/meet-the-fda-s-newly-approved-otc-sunscreen-ingredient-bemotrizinol</loc><lastmod>2026-07-03T19:29:00Z</lastmod><news:news><news:publication_date>2026-07-03T19:29:00Z</news:publication_date>
        <news:title><![CDATA[Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/integrating-suzetrigine-into-acute-pain-care-requires-evidence-access-and-pharmacist-leadership</loc><lastmod>2026-07-03T15:16:00Z</lastmod><news:news><news:publication_date>2026-07-03T15:16:00Z</news:publication_date>
        <news:title><![CDATA[Integrating Suzetrigine Into Acute Pain Care Requires Evidence, Access, and Pharmacist Leadership]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/nih-expands-all-of-us-dataset-to-advance-precision-medicine-across-diverse-population</loc><lastmod>2026-07-03T14:48:00Z</lastmod><news:news><news:publication_date>2026-07-03T14:48:00Z</news:publication_date>
        <news:title><![CDATA[NIH Expands All of Us Data Set to Advance Precision Medicine Across Diverse Population]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/new-climate-model-may-help-predict-influenza-outbreaks-worldwide</loc><lastmod>2026-07-03T14:10:00Z</lastmod><news:news><news:publication_date>2026-07-03T14:10:00Z</news:publication_date>
        <news:title><![CDATA[New Climate Model May Help Predict Influenza Outbreaks Worldwide]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/better-together-real-world-examples-of-pharmacist-provider-collaboration-in-vms-management</loc><lastmod>2026-07-03T12:05:00Z</lastmod><news:news><news:publication_date>2026-07-03T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Better Together: Real-World Examples of Pharmacist-Provider Collaboration in VMS Management]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.pharmacytimes.com/view/the-pharmacist-as-a-menopause-ally-expanding-the-role-beyond-the-prescription</loc><lastmod>2026-07-03T12:00:00Z</lastmod><news:news><news:publication_date>2026-07-03T12:00:00Z</news:publication_date>
        <news:title><![CDATA[The Pharmacist as a Menopause Ally: Expanding the Role Beyond the Prescription]]></news:title>
        <news:keywords><![CDATA[]]></news:keywords>
      </news:news>
	</url></urlset>